Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Assets: 2016-2024

Historic Other Non-Current Assets for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $37.4 million.

  • Akebia Therapeutics' Other Non-Current Assets rose 49.12% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 49.12%. This contributed to the annual value of $37.4 million for FY2024, which is 200.87% up from last year.
  • As of FY2024, Akebia Therapeutics' Other Non-Current Assets stood at $37.4 million, which was up 200.87% from $12.4 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Other Non-Current Assets registered a high of $50.4 million during FY2021, and its lowest value of $5.4 million during FY2022.
  • For the 3-year period, Akebia Therapeutics' Other Non-Current Assets averaged around $18.4 million, with its median value being $12.4 million (2023).
  • As far as peak fluctuations go, Akebia Therapeutics' Other Non-Current Assets crashed by 89.35% in 2022, and later skyrocketed by 200.87% in 2024.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Other Non-Current Assets stood at $38.0 million in 2020, then soared by 32.75% to $50.4 million in 2021, then slumped by 89.35% to $5.4 million in 2022, then skyrocketed by 131.25% to $12.4 million in 2023, then skyrocketed by 200.87% to $37.4 million in 2024.